Dasheng Lu1, Qi Zhang1, Qian Liu1, Kai Wang1, Shengchan Wang1, Qijun Shan2. 1. Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou road, Nanjing, 210029, Jiangsu Province, China. 2. Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou road, Nanjing, 210029, Jiangsu Province, China. qjshan@njmu.edu.cn.
Abstract
BACKGROUND: Comprehensive comparisons of safety (measured by bleeding risk) between multiple novel oral anticoagulants (NOACs and warfarin) in the peri-procedural period of catheter ablation (CA) for atrial fibrillation (AF) are rare. METHODS AND RESULTS: MEDLINE, EMBASE, and COCHRANE LIBRARY were searched up to February 2015 by two reviewers independently. Predefined inclusion criteria identified 24 studies which were included in the analysis. Data were extracted by two researchers, and a network meta-analysis was conducted in R with R2WinBugS package, within Bayesian framework. Pooled odds ratios (OR) and 95% confidence intervals (CI) were summarized to evaluate the bleeding risks of three novel anticoagulants (dabigatran, rivaroxaban, apixaban) in AF patients undergoing catheter ablation (CA). With respect to total bleeding risk, no significant difference was observed between dabigatran, rivaroxaban, apixaban, and vitamin K antagonists (VKAs) by mixed-treatment comparison. The similar results were seen in the direct comparison. While dabigatran was associated with a lower rate of minor bleeding in comparison to VKAs (OR = 0.67 with 95%CI 0.49-0.93). CONCLUSIONS: Risks of bleeding with dabigatran, rivaroxaban, apixaban, and VKAs were similar in peri-procedural period of CA for AF.
BACKGROUND: Comprehensive comparisons of safety (measured by bleeding risk) between multiple novel oral anticoagulants (NOACs and warfarin) in the peri-procedural period of catheter ablation (CA) for atrial fibrillation (AF) are rare. METHODS AND RESULTS: MEDLINE, EMBASE, and COCHRANE LIBRARY were searched up to February 2015 by two reviewers independently. Predefined inclusion criteria identified 24 studies which were included in the analysis. Data were extracted by two researchers, and a network meta-analysis was conducted in R with R2WinBugS package, within Bayesian framework. Pooled odds ratios (OR) and 95% confidence intervals (CI) were summarized to evaluate the bleeding risks of three novel anticoagulants (dabigatran, rivaroxaban, apixaban) in AFpatients undergoing catheter ablation (CA). With respect to total bleeding risk, no significant difference was observed between dabigatran, rivaroxaban, apixaban, and vitamin K antagonists (VKAs) by mixed-treatment comparison. The similar results were seen in the direct comparison. While dabigatran was associated with a lower rate of minor bleeding in comparison to VKAs (OR = 0.67 with 95%CI 0.49-0.93). CONCLUSIONS: Risks of bleeding with dabigatran, rivaroxaban, apixaban, and VKAs were similar in peri-procedural period of CA for AF.
Authors: Mohammed Shurrab; Carlos A Morillo; Sam Schulman; Nitin Kansal; Asaf Danon; David Newman; Ilan Lashevsky; Jeff S Healey; Eugene Crystal Journal: Can J Cardiol Date: 2013-08-29 Impact factor: 5.223
Authors: Daniel W Kaiser; Megan M Streur; Rangadham Nagarakanti; S Patrick Whalen; Christopher R Ellis Journal: J Interv Card Electrophysiol Date: 2013-04-28 Impact factor: 1.900
Authors: Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O Martin; Ayman Hussein; Maurice Khoury; Bernard Abi-Saleh; Samir Alam; Jay Sengupta; P Peter Borek; Bryan Baranowski; Mark Niebauer; Thomas Callahan; Niraj Varma; Mina Chung; Patrick J Tchou; Mohamed Kanj; Thomas Dresing; Bruce D Lindsay; Oussama Wazni Journal: Circ Arrhythm Electrophysiol Date: 2013-04-03
Authors: Amish N Raval; Joaquin E Cigarroa; Mina K Chung; Larry J Diaz-Sandoval; Deborah Diercks; Jonathan P Piccini; Hee Soo Jung; Jeffrey B Washam; Babu G Welch; Allyson R Zazulia; Sean P Collins Journal: Circulation Date: 2017-02-06 Impact factor: 29.690